Factory directly supply 53081-25-7 - Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE – XD BIOCHEM
Factory directly supply 53081-25-7 - Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE – XD BIOCHEM Detail:
Catalog Number | XD90590 |
Product Name | Citicoline sodium |
CAS |
33818-15-4 |
Molecular Formula |
C14H25N4NaO11P2 |
Molecular Weight |
510.31 |
Storage Details | -20°C |
Harmonized Tariff Code | 29349990 |
Product Specification
Appearance | White Solid |
Assay |
99% |
Melting point |
250°C(dec.)(lit.) |
Boiling point |
°Cat760mmHg |
PSA |
238.17000 |
logP |
-0.14090 |
Solubility |
H2O: 100mg/mL |
Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non-US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group and the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had a favorable outcome on the Barthel Index at 90 days. There were no drug-related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.
Product detail pictures:
Related Product Guide:
Using a total scientific good quality management process, superior high quality and excellent faith, we get great name and occupied this field for Factory directly supply 53081-25-7 - Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE – XD BIOCHEM , The product will supply to all over the world, such as: Bogota, Iraq, Finland, Till now, the items list has been updated regularly and attracted clients from around the globe. Comprehensive facts is often obtained in our web-site and you'll be served with premium quality consultant service by our after-sale group. They are likely to help you get thorough acknowledge about our goods and make a satisfied negotiation. Company go to to our factory in Brazil is also welcome at any time. Hope to obtain your inquiries for any pleased co-operation.
By Rosalind from Slovakia - 2018.11.11 19:52
Speaking of this cooperation with the Chinese manufacturer, I just want to say"well dodne", we are very satisfied.
By Belle from London - 2017.09.30 16:36